ArticleApplied microbiology and biotechnology2025
Engineering Bacopa monnieri for improved bacoside content and its neurological evaluation.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role ofNutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacosides are triterpenoidal saponins with numerous pharmacological benefits. One of the significant drawbacks is the low availability of these bacosides. The bacoside pathway is not well elucidated, and there is no prior report of a metabolic engineering approach in this plant. In this study, we have over-expressed the active isoform of Bacopa monnieri squalene synthase (BmSQS1-OE) and silenced the B. monnieri G10H (BmG10H-1-KD), the competitive metabolic pathway, to divert the flux towards triterpene biosynthesis. Absolute quantification of bacosides in these BmSQS1(OE)-BmG10H1(KD) lines has identified improved content of bacoside A3, bacopaside II, and bacoside A. Moreover, the engineered plant extract was also found to have better efficacy on locomotor activity, neuromuscular coordination, and social interaction in a 6-hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Immunohistochemistry of the brain tissues indicates that an extract of enhanced bacoside contents reduces 6-OHDA-induced dopaminergic depletion, implying a potential utility in neurological disorders. KEY POINTS: • The engineered Bacopa monnieri extract has improved amounts of various bacoside. • The engineered Bacopa extract has shown enhanced effectiveness in a 6-hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.